269 related articles for article (PubMed ID: 22372178)
1. Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.
Lee S; White CM
Conn Med; 2012 Jan; 76(1):39-42. PubMed ID: 22372178
[No Abstract] [Full Text] [Related]
2. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
3. New oral anticoagulants for venous thromboembolism prophylaxis in orthopaedic surgery.
Friedman RJ
Instr Course Lect; 2011; 60():291-300. PubMed ID: 21553781
[TBL] [Abstract][Full Text] [Related]
4. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of oral factor Xa inhibitors.
Hylek EM
N Engl J Med; 2010 Dec; 363(26):2559-61. PubMed ID: 21175319
[No Abstract] [Full Text] [Related]
6. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Friedman RJ
Orthopedics; 2011 Oct; 34(10):795-804. PubMed ID: 21956181
[TBL] [Abstract][Full Text] [Related]
7. Factor Xa inhibitors--new anticoagulants for secondary haemostasis.
Perzborn E
Hamostaseologie; 2009 Aug; 29(3):260-7. PubMed ID: 19644596
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery.
Melillo SN; Scanlon JV; Exter BP; Steinberg M; Jarvis CI
Ann Pharmacother; 2010 Jun; 44(6):1061-71. PubMed ID: 20424181
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
10. Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
Komotar RJ; Starke RM; Connolly ES
Neurosurgery; 2008 Oct; 63(4):N10-1. PubMed ID: 18981864
[No Abstract] [Full Text] [Related]
11. [New clinical perspectives in the management of oral direct anticoagulant agents].
Marco P; Zamorano JL; Chana F; Llau JV
Med Clin (Barc); 2014 Feb; 142(4):171-8. PubMed ID: 23866969
[No Abstract] [Full Text] [Related]
12. FDA approves rivaroxaban for prevention of deep-vein thrombosis in surgery.
Aalbers J
Cardiovasc J Afr; 2011; 22(4):218. PubMed ID: 21881694
[No Abstract] [Full Text] [Related]
13. Practical management of new oral anticoagulants after total hip or total knee arthroplasty.
Klauser W; Dütsch M
Musculoskelet Surg; 2013 Dec; 97(3):189-97. PubMed ID: 24249360
[TBL] [Abstract][Full Text] [Related]
14. Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.
Romualdi E; Ageno W
Expert Opin Investig Drugs; 2011 Apr; 20(4):495-505. PubMed ID: 21385107
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
[TBL] [Abstract][Full Text] [Related]
16. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
Harenberg J; Wehling M
Semin Thromb Hemost; 2008 Feb; 34(1):39-57. PubMed ID: 18393142
[TBL] [Abstract][Full Text] [Related]
17. The role of apixaban for venous and arterial thromboembolic disease.
Prom R; Spinler SA
Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
[TBL] [Abstract][Full Text] [Related]
18. Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.
Alves C; Batel-Marques F; Macedo AF
J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):266-76. PubMed ID: 22134134
[TBL] [Abstract][Full Text] [Related]
19. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
[TBL] [Abstract][Full Text] [Related]
20. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Turpie AG; Kreutz R; Llau J; Norrving B; Haas S
Thromb Haemost; 2012 Nov; 108(5):876-86. PubMed ID: 23014816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
